Baseline demographic, clinical, and laboratory data of the study cohort
| Characteristics . | Numbers . |
|---|---|
| N (%) | 151 (100.0) |
| Age, mean (SD), y | 45.6 (17.2) |
| Female, n (%) | 123 (81.5) |
| Hypertension, n (%) | 44 (29.1) |
| Diabetes, n (%) | 10 (6.6) |
| History of TE, n (%) | 99 (65.6) |
| Arterial TE | 21 (13.9) |
| Venous TE | 85 (56.3) |
| Arterial TE and venous TE | 7 (4.6) |
| Pregnancy complications* | 40 (42.1) |
| aPLAs, n (%) | |
| LA alone† | 42 (28.2) |
| LA + anti-β2GPI‡ | 106 (70.7) |
| LA + aCL‡ | 68 (45.0) |
| LA + anti-β2GPI + aCL (triple positivity)‡ | 66 (44.3) |
| Anticoagulation, n (%) | 97 (64.2) |
| LDA | 37 (24.5) |
| VKA | 71 (47.0) |
| LMWH | 14 (9.3) |
| None | 54 (35.8) |
| Concomitant ARD, n (%) | 48 (31.8) |
| SLE | 29 (19.2) |
| LLD | 19 (12.6) |
| Characteristics . | Numbers . |
|---|---|
| N (%) | 151 (100.0) |
| Age, mean (SD), y | 45.6 (17.2) |
| Female, n (%) | 123 (81.5) |
| Hypertension, n (%) | 44 (29.1) |
| Diabetes, n (%) | 10 (6.6) |
| History of TE, n (%) | 99 (65.6) |
| Arterial TE | 21 (13.9) |
| Venous TE | 85 (56.3) |
| Arterial TE and venous TE | 7 (4.6) |
| Pregnancy complications* | 40 (42.1) |
| aPLAs, n (%) | |
| LA alone† | 42 (28.2) |
| LA + anti-β2GPI‡ | 106 (70.7) |
| LA + aCL‡ | 68 (45.0) |
| LA + anti-β2GPI + aCL (triple positivity)‡ | 66 (44.3) |
| Anticoagulation, n (%) | 97 (64.2) |
| LDA | 37 (24.5) |
| VKA | 71 (47.0) |
| LMWH | 14 (9.3) |
| None | 54 (35.8) |
| Concomitant ARD, n (%) | 48 (31.8) |
| SLE | 29 (19.2) |
| LLD | 19 (12.6) |